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CHARACTERIZING THE ROLE OF KISSPEPTIN IN PLACENTAL INVASION 
ZAHRAH MASHEEB 
ABSTRACT 
Preeclampsia is an increasingly prevalent disorder of placentation that has very 
limited options for treatment. The disease is characterized by aberrant invasion of 
placental trophoblasts into the decidualized maternal endometrium. In order to identify 
pathways of therapeutic interest during placentation, we are focusing on the pathway of 
the neuropeptide kisspeptin and its receptor KISS1R, both highly expressed in the human 
placenta. Early functional studies of the ligand-receptor system identified a role for 
kisspeptin in the inhibition of cancer metastasis. Parallels exist between cancer and 
placentation, suggesting the possibility of an inhibitory role for kisspeptin during 
pregnancy as well.  
Existing functional data supports kisspeptin’s inhibitory influence on cellular 
invasion, but the mechanism remains unknown. Evidence for the localization of the 
KISS1R receptor in the current literature was established via a nonspecific antibody and 
requires further investigation. Current literature suggests involvement of the ERK 
(extracellular signal-regulated kinase) pathway as well. Our work aims to solidify the 
localization of kisspeptin and KISS1R, avoiding the use of KISS1R antibodies. Using 
immunohistochemistry for protein localization of kisspeptin and placental fractionation 
followed by quantitative PCR analysis for gene expression, we provide evidence of 
kisspeptin's restriction to the syncytiotrophoblast layer of the placenta, and KISS1R gene 
expression limited to the villous cytotrophoblast layer. This distribution of ligand and 
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receptor suggests a paracrine mechanism for kisspeptin action, with syncytiotrophoblasts 
secreting kisspeptin to act on its receptor on the villous cytotrophoblast layer, and thus 
restricting cytotrophoblast invasion.  
We further attempt to support these data with the use of laser capture 
microdissection of placental tissue to isolate the different layers, followed by quantitative 
PCR. This technique introduced a particularly challenging aspect of working with the 
placenta:  maintaining tissue morphology while also preserving RNA integrity. This 
thesis outlines our troubleshooting process for that technique and introduces alternatives 
for future work. We also employed Western blot analysis of ERK activation to establish 
the mechanism of kisspeptin's inhibitory effect on fractionated trophoblasts. 
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INTRODUCTION 
During pregnancy, the placenta is the interface of gas exchange, nutrient delivery, 
and waste disposal between the fetus and the mother. During placental development, the 
branching network of chorionic villi grows and embeds itself within the decidualized 
maternal endometrium, culminating in a surface area of approximately 12-14 square 
meters (Jauniaux, Poston, & Burton, 2006). Normal placental differentiation involves the 
formation of two types of placental villi: floating villi and anchoring villi (Caniggia et al 
2000). Floating villi are designed for nutrient and gas exchange and are made up of 
villous cytotrophoblasts (CTBs) that differentiate and fuse to create the 
syncytiotrophoblast (STB) layer. The layer of STBs forms an epithelial barrier between 
the villi and the mother’s blood, mediating nutrient and gas exchange and secreting a 
number of hormones, including human chorionic gonadotropin (hCG) and human 
placental lactogen (HPL). CTBs in the anchoring villi (pictured in Figure 1) differentiate 
to either form the STB layer or to break through it as extravillous cytotrophoblasts 
(EVTs) that assemble at the interface and secure the placenta to the uterine decidua.  
These EVTs migrate into the decidua as deep as the first third of the myometrium, 
circling or invading the vasculature to replace the vascular endothelium. This invasion 
triggers the transition of the mother’s spiral arteries, narrow vessels that support a 
hypoxic environment characteristic of the early placenta, into the wider, low-resistance 
uteroplacental arteries that promote oxygen exchange later in gestation.  
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Figure 1. Schematic of an anchoring villus. Adapted from Handschuh et al. (2007) . The 
villous cytotrophoblasts (in yellow) grow and differentiate into the syncytiotrophoblasts 
(green) and the extravillous cytotrophoblasts (red) that invade the mother’s decidua 
(purple). 
 
Abnormal placentation: clinical relevance 
The hypertensive disorders of pregnancy, including preeclampsia, stem from a 
lack of conversion from spiral to uteroplacental arteries (pictured in Figure 2). This defect 
is due to insufficient invasion of the EVTs that are pathologically localized in the basal 
plate rather than extending past this superficial layer to the myometrium. Clinical 
findings include high blood pressure in the mother and often with proteinuria. For the 
fetus, this means a diminished capacity for nutrient exchange, hindering its growth and 
development and sometimes resulting in infant death. Although the relationship between 
impaired EVT invasion and preeclampsia is well established, the mechanism behind it is 
unknown.  
Preeclampsia affects 6 to 8 percent of pregnant women in the United States.  
Paired with seizures, the illness is identified as the more severe eclampsia, the second 
leading cause of maternal death in the U.S. (“High Blood Pressure in Pregnancy - 
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NHLBI, NIH,” n.d.). Unfortunately, the prevalence of preeclampsia is on the rise, and the 
only cure is delivery of the fetus.  Depending on the severity of symptoms, the risks of 
premature delivery are weighed against the risks of the disease. Further, management of 
mild preeclampsia involves the close monitoring of the mother’s blood pressure and 
organ function, significantly contributing to medical costs. Thus, uncovering the 
mechanisms underlying aberrant placentation is crucial to finding alternative treatment 
options for preeclampsia and related disorders, and to finding earlier indicators of the 
disease that can prevent its progression into more severe forms. Our investigation of the 
kisspeptin/KISS1R system aims to uncover a role for this ligand and receptor as an 
indicator or therapeutic target for disorders of placentation such as preeclampsia.  
 
 
Figure 2. Abnormal trophoblast invasion characterizes preeclampsia. A) The normal 
morphology of a spiral artery during the first 6 weeks of placental invasion, and B) the 
normal progression of invasion at 20 weeks and beyond. Notice that in the normally 
developed placenta, EVTs invade the placental bed, altering the vascular morphology. C) 
In preeclampsia, EVTs are restricted to the superficial basal plate. Figure from Caniggia 
and Winter (2002). 
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Kisspeptin: the basics 
The KISS1 gene was initially described for its role in cancer metastasis, first in 
metastatic melanoma, and then in breast carcinoma. The first defining study showed that 
prior microcell-mediated transfer of a human chromosome into two different melanoma 
cell lines conferred a loss of metastatic activity (Welch et al., 1994). To determine the 
gene behind this change, they employed a modified subtractive hybridization method to 
identify mRNA that was uniquely upregulated in the non-metastatic cell line versus its 
metastatic parent, narrowing their scope from a full chromosome to a single gene, KISS1 
(Lee et al., 1996). Upon identifying KISS1 as a candidate, their next study employed 
transfection of the gene into the breast carcinoma line MDA-MB-435, where they 
similarly observed a loss of metastatic activity without any loss of tumorigenicity (Lee & 
Welch, 1997). By 1998, this group localized and sequenced the KISS1 gene and 
determined that its open-reading frame was 145 amino acids long. However, localization 
of the product’s multiple proteolytic cleavage sites and identification of its main 54-
amino acid translated product after cleavage of the full transcript, kisspeptin-54, did not 
occur until 2001 (Ohtaki et al., 2001). In the initial years after its discovery, kisspeptin-54 
was aptly named metastin for its inhibitory role in cancer metastasis. 
A human G-protein-coupled receptor homologous to the rat orphan receptor 
GPR54 was found to be specifically activated by kisspeptin-54, and numerous shorter C-
terminal fragment peptides were also identified. Based on studies of intracellular Ca
2+
 
concentration, C-terminal fragments kisspeptin-14, kisspeptin-13, and kisspeptin-10 also 
activated GPR54 (Muir et al., 2001). Measurements of PIP2 hydrolysis, MAP kinase 
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phosphorylation, and ERK1/2 phosphorylation confirmed that the shortest sequence 
sufficient for receptor activation, the C-terminal decapeptide kisspeptin-10, was as potent 
as kisspeptin-54 and its other shorter fragments (pictured in Figure 3); all were 
comparable enough in their downstream effect on cells over-expressing GPR54 to be 
collectively termed the kisspeptins, and for the receptor to be referred to as KISS1R 
(Kotani et al., 2001). 
 
Figure 3. Kisspeptin gene product and post translational processing. Adapted from 
M. Tena-Sempere (2006).  
 
Aside from extensive study in the context of tumor metastasis, researchers were 
surprised to find that a  loss-of-function mutation in the human receptor for kisspeptin 
(KISS1R) resulted in a clinical case of hypogonadotropic hypogonadism, pointing to an 
entirely new function for the ligand-receptor system in reproduction and puberty (de 
Roux et al., 2003; Seminara et al., 2003). A role in the hypothalamic-pituitary-gonadal 
axis was confirmed with studies showing that mutant mice deficient for the receptor had 
underdeveloped gonads and juvenile reproductive tract development and were responsive 
to exogenous gonadotropin and gonadotropin releasing hormone (GnRH) (Funes et al., 
2003; Seminara et al., 2003). It was evident that in these mice lacking the Kiss1R, that 
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GnRH release was impaired by the lack of the receptor.  Injection of kisspeptin directly 
into the rodent brain stimulated luteinizing hormone (LH) release via GnRH (Gottsch et 
al., 2004) that appeared to be controlled by negative feedback from the sex hormones (V. 
M. Navarro, Castellano, et al., 2004). Functional studies indicated that sustained, cyclical 
intracerebroventricular exposure to kisspeptin induced precocious puberty in female 
rodents and introduced a complex relationship with metabolism through leptin (V. M. 
Navarro, Fernández-Fernández, et al., 2004). The intricacy of this neuropeptide’s role in 
puberty and metabolism is still an active area of research (Víctor M. Navarro & Kaiser, 
2013).  
The discovery of high gene expression levels of both KISS1 and KISS1R in the 
placenta gave rise to an investigation of the system’s role in pregnancy (Ohtaki et al., 
2001). Kisspeptin-54’s original identification as a metastasis inhibitor would support a 
similar function for the peptide in placental invasion, a process likened by many to the 
growth and spread of a tumor but distinguished from cancer by its precise regulation 
(Janneau et al., 2002; Strickland & Richards, 1992). In vitro studies of trophoblast 
migration activity after exogenous treatment with kisspeptin support kisspeptin’s 
inhibitory influence on trophoblast invasion. Treating trophoblasts with kisspeptin causes 
a measurable decrease in migration and outgrowth across multiple models: 1) primary 
trophoblasts isolated from first trimester human placental tissue (Francis, Abera, Matjila, 
Millar, & Katz, 2014), 2) first trimester human villous explants in culture (Bilban et al., 
2004), and 3) a human extravillous cytotrophoblast-derived cell line HTR8/SVneo 
(Roseweir, Katz, & Millar, 2012; Taylor, Pampillo, Bhattacharya, & Babwah, 2014). 
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This inhibitory influence of kisspeptin on trophoblast migration seems to rely on a 
number of downstream effectors, diagrammed in Figure 4. Francis and Taylor both 
showed a resultant increase in ERK1/2 phosphorylation after kisspeptin treatment, while 
Roseweir et al.’s work suggests a link to a receptor-GSK3 beta-FAK feedback loop, a 
focal adhesion kinase involved in cytoskeletal interaction with the extracellular matrix. 
 
 
Figure 4. Kisspeptin/KISS1R system and downstream effectors. Taken from Cvetković 
et al. (2013). Kisspeptin is the ligand for a G-protein coupled receptor, KISS1R, linked to 
phospholipase C and inositol triphosphate second messenger intracellular cascades. 
  
To investigate a more physiologically relevant system that offers the freedom of 
manipulation that human subjects do not, animal models have been developed to study 
the kisspeptin system. With 83% amino acid homology between the rat kisspeptin 
receptor and human KISS1R, measures of kisspeptin levels and localization in the rat 
placenta showed that expression of the ligand and its receptor peak at day 12.5, 
corresponding with the rat placenta’s peak invasiveness (Terao et al., 2004). To study the 
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functional role of the ligand-receptor system in pregnancy, Kiss1 and Kiss1R knockout 
mice were studied in the context of fetal birth weights and placental morphology 
(Herreboudt, Kyle, Lawrence, Doran, & Colledge, 2015). The study concluded that 
mutants of the kisspeptin signaling system produced normally functioning placentas in 
the mouse. Given that expression of Kiss1 was much lower in mouse placenta than is 
seen in humans, the results do not suggest a role for kisspeptin in murine pregnancy but 
do not exclude a role in human pregnancy. 
 
Kisspeptin’s changing expression levels in the human placenta 
In human studies, levels of serum kisspeptin in the mother increase dramatically 
throughout pregnancy and drop abruptly postpartum, suggesting that the placenta is the 
source of this 7000-fold increase in protein (Horikoshi et al., 2003). However, linking the 
rise in circulating protein to an increase in ligand and receptor mRNA within placental 
tissue has proven difficult due to the lack of reliable antibody for localizing the receptor 
and the variability of placental sampling among researchers. One group has shown KISS1 
mRNA and kisspeptin protein to increase over the course of the pregnancy (Qiao, Cheng, 
Zhang, Wang, & Lin, 2005), as may be expected to correspond with the decreasing 
invasiveness of the developing placenta (Strickland & Richards, 1992). In contrast, some 
studies show decreasing levels of placental KISS1 and KISS1R mRNA and protein in 
parallel, while others show the receptor decreasing as the ligand maintains consistent 
levels (Bilban et al., 2004; Janneau et al., 2002). These inconsistencies could be 
explained by sampling differences of the diverse population of trophoblast layers 
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throughout the placenta. The variability of expression levels paired with a skewed 
representation of the trophoblast population in any given experiment could explain why 
some data shows an increase in placental kisspeptin over pregnancy while others report 
just the opposite. 
 The literature on the placental kisspeptin/KISS1R system in preeclampsia (PE) 
demonstrates differential expression compared to that of normal placentas but does little 
to substantiate one particular mechanism of action. Expression of ligand mRNA and 
protein was decreased in placentas collected from mothers with PE, as compared to term 
placentas in one study (Cartwright & Williams, 2012), but was increased in others (Qiao 
et al., 2005; Zhang et al., 2011). Most studies of kisspeptin and PE are limited by the lack 
of gestational age-matched controls for the PE placentas that were collected before term. 
Qiao et al. eventually overcame that challenge by finding premature, otherwise healthy 
age-matched controls for preterm deliveries and eventually confirmed an increase in 
KISS1 and its receptor in “early-onset preeclampsia” (2012). As determined through 
ultrasound evaluation of uterine arteries and measurement of angiogenic factors, 
preeclampsia established before 34 weeks of gestation is more likely to be due to a defect 
in trophoblast invasion than late-onset disease after 34 weeks, which appears to arise 
from preexisting vascular defects and genetic predisposition in the mother (Crispi et al., 
2008; Oudejans & van Dijk, 2008). Decreased kisspeptin during PE versus increased 
kisspeptin in PE support two potential and distinct roles for the ligand. A decrease in 
peptide expression would contradict the idea that kisspeptin serves to inhibit placental 
invasion given that PE is a disease characterized by incomplete invasion of the spiral 
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arteries. However, Smets et al. (2008) postulated that the amount of kisspeptin present 
could be a function of that placenta’s inherent invasiveness and not necessarily a cause of 
the disruption, but rather a result of it. Still, the distinction between early- and late- onset 
preeclampsia may have been a confounding factor in the other studies, supporting the 
theory of the inhibitory tone of the kisspeptin system.  
To complete the story about kisspeptin’s mechanism of action and potential 
relationship to the etiology of preeclampsia, a clearer picture of the system’s location in 
the placenta is required. The data for KISS1 localization suggest that the ligand is 
restricted to the STB compartment, but the data on KISS1R localization is more 
controversial. Many studies rely on immunohistochemistry to identify KISS1R, utilizing 
an antibody of questionable specificity against this G-protein-coupled receptor.  A report 
from Bilban et al. that utilized KISS1R antibody showed ubiquitous KISS1R protein 
expression throughout the placental compartments (2004). Much of the subsequent 
literature has failed to address the confounding nature of the cross-reactive KISS1R 
antibody that was used, limiting a thorough discussion of kisspeptin’s therapeutic 
potential.  
Our research aims to establish the precise localization of kisspeptin and KISS1R 
throughout the layers of the placenta. This would inform us about the direction of 
communication between the trophoblast layers and could shed light on the critical period 
of placental development when this interaction can lead to disease.   
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Objectives 
Given the prevalence of maternal and fetal pathologies due to defective placental 
invasion, we aim to investigate the role of kisspeptin in regulating the migration of 
trophoblasts and their invasion of maternal tissues throughout pregnancy. Studies 
establishing levels of kisspeptin and its receptor are inconsistent in normal and diseased 
placenta, and localization of KISS1R has been limited by the use of an unreliable 
immunohistochemical antibody. The goal of our work is to address those inconsistencies 
and to apply that information toward elucidating kisspeptin’s mechanism of action on 
placenta invasion. 
 
 We will analyze placental fractions for expression levels of KISS1 and KISS1R mRNA by 
real-time PCR as well as kisspeptin protein by immunohistochemistry in order to 
precisely localize them in the STB and CTB compartments.  
 We aim to determine the mechanism by which kisspeptin modulates CTB invasiveness. 
Based on existing data, we hypothesize that kisspeptin inhibits trophoblast invasion 
through upregulation of the ERK1/2 pathway. 
 
With this study, we aim to better understand kisspeptin’s role in placental invasion and 
how this could be manipulated clinically. Given that the only current treatment for 
preeclampsia is delivery of the fetus regardless of its stage of development, an improved 
comprehension of this pathway has valuable therapeutic potential.  
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METHODS 
IRB-approved discarded human tissue collection 
De-identified discarded first and second trimester human placental tissue was 
collected from pregnancy terminations at the Gynecological Procedure Unit at Boston 
Medical Center under IRB approved protocol H-26575.  
 
Immunohistochemistry 
Kisspeptin/HPL/HAI-1 staining 
Placental tissue was flash frozen in liquid nitrogen after a 4 hour fixation in 4% 
paraformaldehyde and cryoprotection in 30% sucrose. 5 μm sections were incubated 
overnight at 4°C with antibodies to kisspeptin, hepatocyte growth factor activator 
inhibitor type I (HAI-1), and/or human placental lactogen (HPL) (ABCAM cat# 
AB11396). Following several washes, sections were incubated in fluorescently-labeled 
secondary antibodies for 1 hour at room temperature and counterstained with DAPI.  
 
HPL/TLR3 staining 
Placental tissue was cryoprotected using a 5-15% sucrose gradient (5% intervals, 
with 30 minutes at each step). Next, the tissue was mounted in rectangular plastic molds 
filled with Optimal Temperature Cutting (OCT) Compound (Tissue-Tek
®
). The mold was 
then frozen on a level block of dry ice, followed by storage at -80°C. Tissue blocks were 
removed from the molds and sectioned at 6 μm using a Tissue-Tek® Cryostat at -20°C. 
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The sections were mounted on Fisherbrand Superfrost Plus slides and allowed to dry 
overnight at room temperature. Slides were fixed for 15 minutes in 10% formaldehyde 
(Polysciences, Inc.). The slides were washed 5 times for 5 minutes each in TBST (1X 
TBS + 0.25% Triton), blocked for 30 minutes in 10% Horse Serum (Vector) and 4% 
Donkey Serum (Jackson Immunoresearch Laboratories) in TBST, and incubated at 4°C 
for 48 hours in primary antibodies: mouse-anti-HPL (ABCAM cat# AB11396) diluted 
1:1000 and rabbit anti-TLR3 (Santa Cruz cat #sc-10740) diluted 1:50 in blocking 
solution. Slides were washed 3 times for 5 minutes each in TBST, and then incubated for 
one hour at room temperature in secondary antibodies from Invitrogen: CY3-anti rabbit 
and AlexaFluor 488-anti mouse, diluted 1:1000 in TBST.  Slides were washed 3 times for 
5 min each in TBST, dried of excess liquid, and coverslipped using Vectashield with 
DAPI (Vector Laboratories). Images were captured using an Olympus BH2 Microscope 
and an attached digital camera. 
 
RNA Extraction  
From whole tissue 
At collection, tissue was minced with sterile scissors and stored in RNAlater (Life 
Technologies) at 4°C for up to two weeks. For extraction, roughly 30 mg of tissue was 
transferred to a 2 mL sample tube (Qiagen cat #990381). 1.2 mL of Trizol (Life 
Technologies) and a sterile 5mm stainless steel bead (Qiagen cat # 69989) were added to 
each sample. Tissue was disrupted and homogenized using the TissueLyser LT (Qiagen) 
and the 12-tube adapter for 8 minutes at a speed of 40 Hz. The samples stood at room 
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temperature for 5 minutes before a 10 minute spin at 12,000 x g to pellet cell debris. The 
supernatant was transferred to a new 1.5 mL tube, and 250 μL of chloroform was added 
to each sample in a fume hood. After vortexing vigorously for 30 seconds, the samples 
stood at room temperature for 5 minutes before centrifugation at 10,000 x g for 10 
minutes.  The top aqueous layer was collected and transferred to another 1.5 mL tube. 
Next, the protocol for the RNeasy Mini Kit was followed to achieve RNA extraction via a 
spin column that binds RNA (pictured in Figure 5 below).  
 
 
 
Figure 5. RNeasy Mini Kit Protocol. (QIAGEN RNeasy Mini Handbook, 2012, p. 9) 
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Briefly, 70% ethanol was added 1:1 to the sample (roughly 600 μL). The sample was 
spun to bind RNA to the column, followed by washes to clear unwanted contaminants. 
The membrane of the column was treated with RNase-free DNase I (Qiagen cat #79254) 
to degrade DNA contaminants, washed, and eluted in a volume of 30 μL RNase-free 
water. To improve RNA yield, the spin column was eluted for a second time with the 
same 30 μL eluent. RNA was quantified using Gen5 spectrophotometric nucleic acid 
quantification software on the Biotek Synergy HT Microplate Reader. 
From fractionated cells 
Pellet was disrupted and homogenized in a volume of Buffer RLT (Qiagen) 
specified in Table 1. The protocol above is resumed by adding ethanol and carrying out 
steps as described (pictured on the left column of Figure 5).  
 
Table 1. Qiagen handbook designations for lysis buffer volume based on number of 
cells. 
Number of pelleted cells Volume of Buffer RLT (μL) 
< 5×10
6
 350 
5×10
6
 – 1×107 600 
 
Reverse Transcription 
To obtain stable DNA that is complementary to the previously extracted RNA, we 
used the SuperScript® III First-Strand Synthesis System (Life Technologies). The kit 
contains all the necessary reagents and buffers for optimum use of the provided reverse 
transcriptase enzyme. Oligo(dT)20 was used (see left pathway of Figure 6) as the primer 
for synthesis of cDNA.  Negative controls, containing deionized water in the place of 
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reverse transcriptase, were included in the experiment. CDNA products were stored at -
80°C before use in quantitative PCR.  
 
Figure 6. SuperScript III Reverse Transcription Protocol. Diagram taken from page 1 
of user manual (Life Technologies cat # 18080-051) (“SuperScript®III First-Strand 
Synthesis System for RT-PCR,” 2013) 
 
Quantitative Polymerase Chain Reaction (qPCR) 
All reagents were thawed on ice to prevent degradation of samples and 
polymerases. 2 μL of cDNA (product of the reverse transcription) were used per reaction 
with  TaqMan® Gene Expression Assays. Each assay contained primers that flanked 
either KISS1 (Genbank Accession #NM_002256.3), KISS1R (Genbank Accession 
#NM_032551.4), HPL (Genbank Accession # J00118.1), or GAPDH (Genbank 
Accession # JN613429.1), as a housekeeping gene for normalization. Reactions were 
performed in duplicate and mixed as shown in Table 2. Negative controls for each 
specific Gene Expression Assay were also included by using water in the place of cDNA 
in one well. 
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Table 2. PCR reaction mixture using Taqman primers. 
 
PCR reaction mix component 
Volume per 20-uL reaction (μL) 
Single reaction Two replicates 
20X TaqMan® Gene Expression Assay 1.0 2.1 
cDNA template + RNase-free water 9.0 18.9 
2X TaqMan® Gene Expression Master Mix 10.0 21 
Total Volume 20.0 42 
 
96 well-plates containing the reagents were sealed and placed in an Applied 
Biosystems 7500 Real-Time PCR System with the thermocycling program outlined in 
Table 3.  
Table 3. Thermocycling program used. 
Stage Temp (°C) Time 
Hold 50 2 min 
Hold 95 10 min 
Cycle 
(40 Cycles 
95 15 sec 
60 1 min 
 
Ct values were exported to Microsoft Excel for analysis. Ct values were then 
normalized to GAPDH expression and averaged between duplicates.  
 
Placental Fractionation 
Placentas collected for fractionation were immediately rinsed in sterile Phosphate 
Buffered Saline (PBS) containing antibiotics, and all visible blood clots were removed. 
Tissue was kept on ice in sterile media also containing antibiotics, while branched 
terminal villi were dissected free into solution using sterile tweezers and scissors over a 
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light box. Placental villi were pooled and spun down in a centrifuge (8 min at 1300 rpm). 
The supernatant was discarded, and tissue was weighed to determine the appropriate 
amount of enzyme to use for digestion (pictured in second column of Table 4). Solutions 
of collagenase and trypsin were made to accommodate multiple rounds of digestion in a 
37°C shaking water bath. At each step, a drop of supernatant was examined under a 
microscope to identify the majority cell type that had come off of the villi and into 
solution.  
 
Table 4. Enzymatic incubation times and volumes.  
Enzyme Step Amount (mL) Time 
Collagenase 1 (C1) Mass * 6 6 min 
Trypsin 1 (T1) Mass * 6 6 min 
Trypsin 2 (T2) Mass * 5 4.5 min 
Trypsin 3 (T3), if needed 20  
Collagenase 2 (C2) 10 (<20 grams) 
20 (>20 grams) 
2.5 min 
 
C1 was drawn out until some CTBs and some STBs were visually present under 
the microscope. T1 supernatant featured more CTBs than STBs, and T2 contained mainly 
CTBs and not fibroblasts, a connective tissue component that measures a similar density 
as CTBs and thus cannot be separated through density centrifugation. T3 was only 
collected if more CTBs could be salvaged without including fibroblast contamination. 
Supernatant with the appropriate composition was collected, quenched of enzymatic 
activity with 5 mL fetal bovine serum, and passed through a sterile gauze filter. The 
supernatants were spun (8 min at 1300 rpm, 4°C) and the pellet was digested with C2 to 
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separate clumps. Once again, cells were spun and the pellet was resuspended in serum 
free media to undergo Percoll gradient centrifugation. The cells in serum free media were 
slowly layered on top of the gradient without disturbing the strata and centrifuged for 25 
min at 2700 x g, 4°C. CTB and STB layers were collected separately and washed in 
sterile media. Removal of CD45-positive leukocytes and CD9-positive fibroblasts is 
carried out by immunomagnetic separation with the EasySep Biotin Positive Selection 
Kit (StemCell).  A portion of purified cells is subjected to staining with cytokeratin 7 
antibody to assess final purity. Finally, cells were counted and kept on ice for use the next 
day for qPCR, Western blotting, or migration assays, or frozen in Recovery Cell Culture 
Freezing Medium (Life Technologies). 
 
Culture of JEG-3 Cells 
The choriocarcinoma JEG-3 immortalized cell line (a generous gift from Dr. 
Danny Schust) was cultured in a Sanyo CO2 Incubator at 37°C in RPMI 1640 media 
(Fisher Scientific) with added 10% Fetal Bovine Serum (Life Science) and 1% 
Penicillin/Streptomycin (Life Technologies, 100X). Cells were passed when 70-90% 
confluent and grown in cell culture dishes (60 mm, BD Falcon).  
 
Laser-Capture Microdissection (LCM) 
At collection, placental tissue was rinsed of blood, immediately embedded in 
OCT, and frozen on dry ice. Tissue blocks were sectioned at 10 μm using a cryostat, and 
sections were mounted onto RNase-free plain glass slides. Slides were stained using an 
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abbreviated hematoxylin and eosin procedure adapted from an Arcturus protocol 
designed for LCM. The slides were dipped sequentially into autoclaved Coplin jars 
containing staining solution, washing solution, and increasing concentrations of ethanol 
(ETOH) for dehydration. All solutions were RNase-free.  The full procedure is outlined 
in Table 5. 
 
Table 5. LCM staining procedure from Arcturus. 
Solution Time 
70% ETOH  30 seconds 
dH2O 30 seconds 
Hematoxylin 30 seconds 
dH2O 30 seconds 
Bluing reagent (dH2O) 30 seconds 
70% ETOH 30 seconds 
95% ETOH 30 seconds 
Eosin  15 seconds 
70% ETOH 30 seconds 
95% ETOH 30 seconds 
100% ETOH (fresh each time) 30 seconds 
Xylenes 5 minutes 
Air dry in a fume hood 5 minutes 
  
After drying, slides were examined under a light microscope to assess tissue 
morphology and staining. They were stored with desiccant at -80°C until use for laser 
capture. Laser capture microdissection was first performed using an Arcturus Pixcell IIe 
at the Boston University School of Medicine Laser Capture Microdissection Core 
Facility, a microscope that employs an infrared laser beam directed by the user with a 
moveable stage and joystick. The laser contacts the special polymer surface of the 
CapSure LCM HS Cap (not the tissue) and to make the designated area adhesive. When 
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the cap is lowered onto the tissue, cells that contact the adhesive are pulled from their 
surroundings. At the end of the session, the caps (with all of the harvested cells attached) 
are washed in lysis buffer and processed for RNA extraction.  
The LCM protocol was later modified as follows:  the placental tissue was 
collected into sterile 5% sucrose as the first of a three-step dehydration gradient for 
protection of morphology during freezing (5% for 30 minutes, 10% for 30 minutes, 15% 
for 30 minutes). The dehydrated tissue was then embedded in OCT and flash frozen in 
liquid nitrogen. 10 μm sections were cut using a cryostat, and sections were mounted on 
polyethylene naphthalate (PEN) membrane glass slides (Arcturus) compatible with the 
UV-powered Leica laser capture system (Model AS LMD; Leica, Wetzlar, Germany) at 
the Schepens Eye Institute. Slides were stained using the protocol previously described 
(Guller et al., 2008). Briefly, slides were dipped sequentially in for 15 seconds each in 
95% ETOH, 70% ETOH, and deionized water, followed by staining with Mayer’s 
Hematoxylin (Sigma) for 30 seconds. Slides were rinsed twice with deionized water for 
15 seconds each, washed with 70% ETOH for 15 seconds, and counterstained with Eosin 
Y (Sigma) for 5 seconds or less.  Finally, slides were dehydrated by placement into 95% 
ETOH twice for 15 seconds each, twice in 100% ETOH for 15 seconds each, and 
Xylenes for 60 seconds. The slides are allowed to air dry for two minutes before storage 
at -80°C in the presence of a desiccant, until they are thawed slowly (15 minutes at -
20°C, 15 minutes at 4°C) for use on the LCM microscope at room temperature. The Leica 
LCM system employs a UV laser that contacts the tissue directly and detaches it from the 
slide by severing the PEN membrane from the glass. Microdissected cells were captured 
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into 1.5 mL microcentrifuge tube caps containing RLT buffer from the Qiagen RNeasy 
Micro Kit.  
The final protocol modification for LCM involved collection of placental tissue 
directly into RNAlater. The tissue was placed in 15% sterile sucrose for 30 mins as an 
abbreviated cryoprotection method. Next, tissue was embedded in OCT and flash frozen 
using an ethanol bath in liquid nitrogen (-95°C) for the most rapid freezing to minimize 
ice crystal formation. Tissue was sectioned and stained using the Guller method 
described above, and RNA was extracted at multiple steps along the way to confirm 
presence of adequate levels of RNA. RNA was extracted using the RNeasy Micro Kit.  
Nucleic acid quantification was performed using a Biotek Synergy HT microplate reader 
and Gen5 spectrophotometry software.  
 
Invasion Assay 
250,000 cells were seeded on Matrigel (diluted 1:8) coated transwell membranes 
and allowed to invade towards decidua-conditioned media for 12 hours. Invasive 
trophoblast cells on the bottom side of the membrane were fixed in 4% paraformaldehyde 
and identified by cytokeratin-7 staining. The images were processed and counted by an 
automated thresholding algorithm. 
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Western Blot for p-ERK and ERK 
10
6
 cells (either JEG-3 or fractionated trophoblasts) were plated in each well of a 
6-well plate, incubated overnight, and serum starved for 3 hours before kisspeptin 
treatment. Cells were treated in duplicate with vehicle, kisspeptin at 10
-7
 M for 5 minutes, 
or phorbol 12-myristate 13-acetate (PMA, a direct activator of protein kinase C) at 10
-7
 M 
for 20 min, all at 37°C. The plate was then placed on ice to end the reaction and washed 
twice with cold PBS before lysis with the following freshly prepared lysis solution: 
 RIPA buffer, 1X   1 mL 
 PMSF     5 μL 
 Sodium orthovanadate  5 μL 
 Protease inhibitor cocktail  10 μL   
Cells were treated with 350 μL RIPA lysis solution per well for 30 min shaking at 
4°C.  Lysates were then collected into Eppendorf tubes and centrifuged at 12,000 rpm for 
10 min at 4°C to pellet cell debris. Supernatants were transferred to fresh tubes and kept 
on ice during protein quantification. The Pierce BCA Protein Assay was used to measure 
protein concentrations with a microplate reader after reaction with a colorimetric 
substrate, alongside a standard curve of bovine serum albumin (BSA). Standards were 
made by performing six serial 1:2 dilutions of the BSA solution included in the kit (with 
a starting concentration of 2 mg/mL) with deionized water. 25 μL of each standard was 
arranged sequentially in the wells of a clear flat-bottom 96-well plate. 25 uL of each 
protein lysate was also added to the plate, plus one well of RIPA lysis solution as a blank. 
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Next, 4 ml of BCA Solution A was mixed with 80 uL of BCA Solution B, and 200 μL of 
the mixture was added to each sample, standard, and blank in the plate. The plate was 
covered with Parafilm ® M and incubated for 30 minutes at 37°C. Absorptions were 
recorded after excitation with 589 nm light.  
Samples were diluted 3:1 using 4X Laemmli Sample Buffer (BIO-RAD) for SDS-
PAGE and 10:1 with β-mercaptoethanol in a final volume of 30 μL,and then boiled at 
95°C for 5 minutes to denature the proteins. Samples and a protein ladder were loaded 
onto a 4–20% Mini-PROTEAN® TGX™ Gel in a BIO-RAD electrophoresis chamber 
filled with 1X Running Buffer (Tris/Glycine/SDS). The gel was run for 1 hour at 100V in 
a stirred ice bath. Proteins were then transferred to a nitrocellulose membrane using the 
BIO-RAD transfer chamber attachments, run for 1.5 hours at 70V in a stirred ice bath. 
The membrane was washed with 1X TBST, blocked for one hour in 4% nonfat dry milk, 
and incubated with mouse anti-p-ERK antibody (Santa Cruz, sc-7383) at 1:10,000 in 
TBST + 4% milk overnight at 4°C. The membrane was washed for 30 min and incubated 
with a horseradish peroxidase-anti mouse antibody (Santa Cruz) at 1:1000 for one hour at 
room temperature. The Amersham ECL Western Blotting Detection Reagent kit was used 
for chemiluminescent detection of the protein bands, and the image was exposed onto 
film. The membrane was then washed with Restore Western Blot Stripping Buffer and 
reprobed with goat anti-ERK antibody to serve as a loading control followed by HRP-anti 
goat secondary antibody and the same development process.  Band intensity was 
compared after quantification with ImageJ. 
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Statistical analysis 
Analysis of the qPCR and Western blotting results was performed when the 
number of values was equal to or greater than three. All statistical analyses was 
performed with ANOVA using Instat 3.0 (GraphPad Software) and using a two-tailed t-
test (P <  0.05). 
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RESULTS 
 
Preliminary Data 
Immunofluorescence of placental villi confirm KISS1 localization in the STB 
compartment 
As a proof of concept, we aimed to confirm the localization of kisspeptin protein 
in the syncytiotrophoblast compartment, as previously reported by Bilban et al. (2004). 
Utilizing an antibody against human placental lactogen (HPL) as a positive control for 
STB staining and an antibody against hepatocyte growth factor activator inhibitor-1 
(HAI-1) as a positive control for the villous CTB compartment, Upadhyay et al. (2012) 
were able to show overlap between kisspeptin and HPL staining in the STB layer in both 
first and second trimester placentas. Figure 7 features a pattern representative across both 
trimesters. HAI-1 staining did not overlap with kisspeptin, signifying that kisspeptin 
expression was limited to the STB and not the CTB layer. These results are in line with 
the current literature, suggesting that the STBs may be responsible for the secretion of the 
ligand.  
Subsequent staining experiments attempting to utilize the HAI-1 antibody 
revealed that it was not a reliable marker for the CTB compartment and sometimes stains 
STBs. As a result, it was necessary to seek out an alternative marker for CTBs (see 
Current Findings).  
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Figure 7. Kisspeptin protein expression overlaps with a staining for an STB-specific 
protein, HPL. A,D: HPL stains the STB compartment. B: HAI-1, an identifier of the 
CTB compartment stains differently than kisspeptin (E). C,F: While HPL and HAI-1 do 
not overlap, HPL and kisspeptin do, indicating that kisspeptin is expressed primarily in 
the STB compartment. Taken from Upadhyay et al. (2012).  
 
KISS1 mRNA expression predominantly found in STBs, while KISS1R only in CTBs 
After fractionating each placenta and isolating the STB and CTB cell fractions, 
RNA was extracted from those fractions and subjected to real-time quantitative PCR 
(RT-qPCR) analysis with primers for KISS1, KISS1R, HPL, and GAPDH (a housekeeping 
gene), as shown in Figure 8. HPL was used as a positive identifier of the STBs. Data 
were pooled from 11-17 week gestational age placentas and normalized to GAPDH 
expression, resulting in 25.2±7.7 fold higher KISS1 mRNA levels in STBs than CTBs 
(p<0.05) and 23.1±6.9 fold higher KISS1R mRNA levels in CTBs than STBs (p<0.05) 
(Upadhyay et al., 2012). These results support the immunofluorescence data, placing the 
KISS1 transcript in the same compartment as the kisspeptin protein.  
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Figure 8. KISS1R was found to be predominantly expressed in the purified 
cytotrophoblast population, while KISS1 expression was primarily found in the 
syncytiotrophoblast. Via qPCR of fractionated trophoblasts, KISS1R mRNA levels were 
23.1±6.9 fold higher in CTB relative to STB from the same placenta. In contrast, KISS1 
mRNA levels were 25.2±7.7 fold higher in STB. Human placental lactogen (HPL) was 
used to identify STBs and mRNA levels were normalized to GAPDH. n=5; *p<0.05 
Taken from Upadhyay et al. (2012). 
 
Kisspeptin-10 inhibits trophoblast invasion 
To address our second aim, Upadhyay et al. (2012) performed invasion assays to 
determine the effects of kisspeptin treatment on the migratory behavior of primary 
trophoblasts (see Figure 9). Cells treated with 100 pM of kisspeptin-10 had a significantly 
lower invasion index than the control (p<0.05). Inhibition of migration increased in a 
dose-dependent manner, as summarized in Figure 9, as 100 nM of kisspeptin-10 
significantly decreased invasion yet more than 100 pM kisspeptin-10 (p<0.01).  
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Figure 9. Treatment with kisspeptin-10 inhibits cytotrophoblast invasion in a dose-
dependent manner. Invading CTBs were stained for cytokeratin-7 (green) and 
counterstained with DAPI (blue). Representative images are shown for transwell 
membranes with no treatment (A), 1 pM (B), 100 pM (C), and 100 nM kp-10 (D). 
Treatment with 100 pM and 100 nM kp-10 reduced invasion to 64±8% and 48±10% of 
untreated controls, respectively (E). Treatment with a lower dose of 1 pM kp-10 yielded 
no significant effect. n=5; *p<0.05; **p<0.01. Taken from Upadhyay et al. (2012). 
 
Kisspeptin/KISS1R pathway still under investigation 
Fractionated trophoblasts were treated for five minutes with kisspeptin-10, lysed, 
and probed for activation of ERK to phosphorylated ERK (p-ERK) (Figure 10). PMA 
was used as a positive control and increased band intensity by an average fold change of 
2.07. Kisspeptin, on the other hand, did not produce a significant change in p-ERK 
protein.  Additional time points and doses of kisspeptin will be assayed.  
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Figure 10. Western blot shows no increase in ERK activation after treatment with 
kp-10. Left: p-ERK Western blot of lysates from primary trophoblasts shows an increase 
in band density (measured by ImageJ) for PMA treatment at 200 uM (positive control) 
but none for Kisspeptin-10 at 100 uM. Kiss = 5 minutes, PMA = 20 minutes.  
 
Current Findings for this Thesis 
TLR3 as a marker for CTBs 
Immunofluorescence staining with TLR3, an immunological marker, has 
introduced a new possibility for identifying the CTB layer, as TLR3 appears to stain this 
layer more consistently than HAI-1. Figure 11, panel A shows TLR3 concentrated to the 
inner villous cytotrophoblast layer, while in panel B HPL staining identifies the outer 
syncytiotrophoblast layer. The combination filter on the epifluorescent microscope in 
panel C shows specific staining for the two layers that is shown more clearly in panel D, 
composed of merged images from panels A and B.  
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Figure 11 TLR3 Staining of the placenta. A) TLR3 selectively stains the CTB layer. B) 
HPL consistently stains the STB layer. C) Combination filter image shows that the two 
layers are distinctly stained, and D) Merged images A and B show no overlap between 
TLR3 and HPL staining.  
 
Location of KISS1R by in situ hybridization  
Given that the localization of KISS1R in trophoblast layers is controversial due to 
the lack of KISS1R antibody specificity, we wished to support our finding that KISS1R is 
restricted to the CTB compartment by confirming with another method of mRNA 
measurement. We had some difficulty finding a reliable positive control for the CTB 
layer in the qPCR experiments (HPL was reliable for the STB fractions).  Thus, we 
desired secondary confirmation of our results through another experimental modality and 
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considered in situ hybridization for KISS1R. In order to determine the feasibility of in situ 
hybridization to localize KISS1R mRNA visually to the inner trophoblast layer, we first 
needed to determine the bulk levels of KISS1R expression in the placenta. KISS1 levels 
were challenging to detect by in situ hybridization by our collaborators due to high 
background signal (data not shown), and thus levels of KISS1R would need to be 
comparable to those of KISS1 for minimal visualization of the transcript above 
background noise. QPCR of unfractionated 8 week and 16 week placental samples 
normalized to GAPDH expression (Figure 12) showed that, when compared to the 8 
week expression of KISS1R, 8 week KISS1 mRNA expression is 800 times higher than 
KISS1R and 16 week expression of KISS1 is even greater at roughly 1400 times higher 
expression. On the other hand, 16 week KISS1R is even lower than it is at 8 weeks. This 
is in agreement with literature that suggests increasing levels of kisspeptin throughout 
gestation and decreasing levels of the receptor. The vast difference in mRNA expression 
of receptor and ligand suggests that reliable detection of the receptor by in situ 
hybridization may be difficult.  
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Figure 12. KISS1 and KISS1R expression in unfractionated first and second 
trimester placentas. qPCR was performed in duplicate, but n=1 for each gestational age. 
HPL was used as a positive control. 
 
Laser capture microdissection: tissue morphology and RNA quantity 
Tissue preparation for LCM required extensive optimization to achieve suitable 
tissue morphology for trophoblast identification and RNA quantity sufficient for eventual 
qPCR analysis. With each attempt, we adjusted our methods of collection, freezing, 
staining, drying, and laser capture to improve cell morphology/identification and our final 
yield of RNA. Methods that improved cell morphology seemed to have detrimental 
effects on RNA preservation. As a result, optimization of this technique is ongoing.  The 
following results represent our progress.  
 Our protocol was originally optimized for tissue morphology, and we determined 
that a UV-powered LCM system would be best to address our specific needs. We 
performed LCM to collect CTBs separately from STBs, and intended to use the enriched 
cell populations to perform qPCR analysis. After extracting RNA from the dissected 
samples, quantification revealed a negligible amount of RNA for both the CTBs and 
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STBs collected, summarized in Table 6. Further, the 260/280 absorbance ratios were 
much lower than the value of 2 that is considered a sign of RNA purity.  
 
Table 6: RNA quantification after LCM of CTBs and STBs. 
Sample 260/280 ng/µL 
CTB 0.5 -0.836 
STB 1 -2.487 
 
Given the lack of RNA yield, we next decided to sample the tissue at different 
steps in the preparation process to determine at which step(s) RNA loss occurred. The 
laser capture dissection process itself takes place for an extended period of time at room 
temperature, resulting in expected RNA degradation, so determining the yields before 
that step would indicate the maximum amount of RNA achievable under ideal conditions. 
We sampled tissue after being embedded and flash frozen in liquid nitrogen, and again 
after staining (with or without a one hour drying step). The results, summarized in Table 
7, reflect the presence of RNA throughout the preparation process with a steep drop off 
between freezing and staining. However, a starting value of less than 40 ng/µL after 
freezing indicated a need for a closer investigation of RNA loss during the collection and 
freezing process. We needed to re-optimize the procedure, eliminating steps that could 
interfere with RNA integrity.   
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Table 7. RNA quantification of tissue sampled after A) embedding and flash freezing 
in liquid nitrogen, B) staining without a drying step, and C) staining with a drying time of 
one hour at room temperature. 
Sample 260/280 ng/µL 
A. Frozen tissue block 1.679 39.298 
B. Stained w/o drying 1.5 4.974 
C. Stained, dried one 
hour 
(pictured in Figure 13A) 
1.25 4.125 
 
 
While snap freezing in liquid nitrogen can be the fastest method of freezing to 
avoid crystal formation (since it is the coldest at roughly -190°C), direct submersion in 
liquid nitrogen can cause bubbles to form around the tissue, cell rupture, and RNase 
release/activation as the nitrogen vaporizes. To avoid this issue, we switched to using an 
ethanol bath cooled to -95°C by liquid nitrogen. Some crystal formation in the placental 
tissue during freezing was unavoidable due to the large amount of water present in the 
tissue. Our best tissue morphology was achieved by putting the tissue through a three step 
5-15% sucrose gradient for dehydration and cryoprotection, followed by an abbreviated 
staining procedure. However, to improve our yield of RNA, we tried collecting the tissue 
into RNAlater solution to protect the tissue from degradation by endogenous RNases. 
Unfortunately, tissue kept in RNAlater becomes dehydrated to the point that it is very 
difficult to cryosection. As a compromise, we employed an abbreviated sucrose gradient 
by taking the tissue from RNAlater and soaking it in sterile RNase-free 15% sucrose for 
30 minutes. Again, we sampled tissue at various points throughout the preparation: 
directly from collection into RNA extraction solution (buffer RLT) to determine the 
absolute maximum yield, after RNAlater and 15% sucrose, after freezing in the ethanol 
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bath, after sectioning and mild fixation, and finally after staining. The results of this 
extraction, summarized in Table 8, indicate a vast improvement in the concentration of 
RNA after staining, by roughly a factor of 8 from the previous trial.  
 
Table 8. RNA quantification of tissue sampled A) immediately at collection, B) after 
equilibration in RNAlater and 30 min in 15% sucrose, C) after embedding and freezing in 
an ethanol bath cooled with liquid nitrogen, D) after sectioning and acetone fixation, and 
E) after staining. 
Sample 260/280 ng/µL 
A. Collected into RLT 1.926 391.304 
B. Collected into 
RNAlater, 15% sucrose 
1.967 147.906 
C. Frozen tissue block   
(-95°C ETOH) 
1.886 283.855 
D. Cut + Fixed in acetone 2.091 18.631 
E. Stained 
(comparable section 
shown in Figure 13B) 
2.235 32.224 
 
However, the improvement in RNA yield was accompanied by a loss of 
morphology. Figure 13A features a section of tissue from the previous RNA 
quantification trial, which underwent a full sucrose gradient. Figure 13B shows a 
representative section from a placental sample collected into RNAlater, processed the 
same way as the tissue from the second RNA quantification trial. The epithelium of the 
tissue with higher RNA yield is torn and crystallized, impossible for use in LCM. 
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Figure 13 Placental tissue processed and stained for LCM. A) Tissue was processed 
optimally to preserve morphology by undergoing a complete sucrose gradient and drying 
one hour at room temperature after staining. B) Tissue was processed to preserve RNA 
quality through collection into RNAlater and use of a single 15% sucrose step to 
reestablish some natural morphology, without any drying at room temperature. The 
staining procedure was otherwise identical for both sections.  
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DISCUSSION 
 
Confirming KISS1R localization  
Preliminary qPCR data from fractionated samples suggests that KISS1R 
expression is restricted to villous cytotrophoblasts, contradicting the report from Bilban et 
al. in 2004 that observed receptor expression throughout the placental compartments 
using a nonspecific antibody against KISS1R. While this is a step toward establishing the 
separation of kisspeptin ligand and receptor in the placenta, our conclusion would be 
better supported if we could find a reliable and consistent marker that distinguishes 
CTBs. By verifying the purity of our enriched CTB sample after fractionation, there 
would be no question as to the localization of KISS1R in the villous cytotrophoblasts.  
Our discovery of TLR3 expression by the CTB layer and not the STB layer in the 
placenta suggests that a marker may exist to solve this problem. However, the use of an 
immunological marker would allow no distinction between CTBs and any leukocytes that 
distributed throughout the tissue. In future work we plan to subject purified CTB and 
STB fractions to qPCR with KISS1, KISS1R, HPL, and TLR3 primers.  TLR3 would be 
expected to serve as the reliable marker for the CTB fraction that was missing from our 
experiments previously. With secondary magnetic purification steps to remove 
contamination from leukocytes, we could avoid that confound and confirm the 
distribution that our current data suggests.  
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Balancing specificity, morphology, and RNA quality for LCM 
After realizing that in situ hybridization was not a feasible alternative, we turned 
to laser capture microdissection to confirm the localization of KISS1R expression.  Our 
goal for laser capture microdissection was to visually identify the placental cell layers 
with hematoxylin and eosin staining and then to separate out the villous CTB layer from 
the STB layer using a laser, ideally one equipped to dissect on the scale of a single cell 
layer. During our original attempt to microdissect tissue at the Boston University School 
of Medicine LCM Core Facility, it became clear that the early model LCM system there 
was too crude to separate one cell layer from another. In the Arcturus Pixcell IIe, the 
diameter of the laser beam exceeded the diameter of our layer of interest. Additionally, 
the use of a system with an infrared laser relied on adhesion of the tissue to an activated 
membrane on the LCM cap, without any contact between the laser and the tissue. While 
the force of adhesion to the cap is likely sufficient for pulling particular sections of tissue 
away from others (for example epithelia from parenchyma), separating two functionally-
related and adjacent single-cell layers from one another requires much more precision 
that may be achieved through an ultraviolet laser LCM system. Based on our 
observations, it was nearly impossible to prevent connective tissue contamination using 
an IR laser.  
The caveat to using a UV-powered system, however, is that direct contact 
between the cells and the UV light can cause a striking change in the gene expression 
profiles of those cells. In addition to the RNA degradation and gene expression shifts 
expected to result from the stress of a lengthy tissue preparation, preserving tissue 
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morphology while also maintaining RNA quality is particularly challenging in the 
placenta, given the high water content and high level of endogenous RNases. As a result, 
freezing artifact is difficult to prevent without proper fixation, which would damage the 
RNA. Additionally, the many RNases present in placental tissue contribute to an 
abbreviated timeline for RNA stability (Fajardy et al., 2009), shortened further by the 
RNase contamination from vaginal exposure during delivery/collection (Cindrova-Davies 
et al., 2007). Collecting the tissue directly into RNAlater after rinsing was one way to 
prevent tissue RNases from degrading the RNA (Fajardy et al., 2009), but the protective 
solution caused crystal formation that, in our experience, was very disruptive to tissue 
morphology. Thus, we have concluded that the extensive and delicate process required 
for LCM is not ideal to address our hypothesis. QPCR analysis of fractionated placenta 
(as described in Figure 8) has proven a far more reliable method of identifying distinct 
trophoblast layers and preserving the integrity of their RNA. This method avoids the need 
to optimize tissue morphology and will allow us to localize KISS1R expression levels 
more precisely, again stressing the importance of finding unique gene identifiers for each 
trophoblast layer in the placenta. 
 
Model for kisspeptin activity in the developing placenta 
Although we are still in the process of finding a way to confirm the localization of 
KISS1R, we can speculate that if our hypothesized localization of KISS1 to the 
syncytiotrophoblast and KISS1R to the villous cytotrophoblast holds true, it would 
support the idea of a paracrine mechanism with the syncytiotrophoblast directing KISS1R 
action in the villous cytotrophoblast, the invasive component of the placenta, with 
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production of KISS1. As shown in Figure 14, STBs release kisspeptin that diffuses to 
nearby CTBs that are differentiating into extravillous trophoblasts (EVT) that invade 
maternal tissue. Based on our invasion assay data, kisspeptin could be a regulator of EVT 
invasion, acting to inhibit invasive activity as gestation progresses. Further, kisspeptin 
has been previously shown to activate an ERK1/2 pathway, and although our Western 
blotting experiments have yet to confirm this connection, we intend to continue 
investigating this mechanism with experiments including different incubation times and 
kisspeptin doses.  
 
Figure 14 Proposed kisspeptin-KISS1R signaling loop in fetal villi. Pink: KISS1 
expressed in the syncytiotrophoblasts. Yellow: KISS1R expressed in villous 
cytotrophoblasts differentiating and invading the decidua as extravillous 
cytotrophoblasts. The black squares represent kisspeptin protein that is released from the 
syncytium, inhibiting the invasion of extravillous cytotrophoblasts. 
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